Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
- Arexvy may be administered concomitantly with inactivated seasonal influenza vaccines (standard dose unadjuvanted, high dose unadjuvanted, or standard dose adjuvanted).
ADMINISTRATION
AREXVY is supplied in 2 vials for reconstitution1
Administer 1 dose (0.5 mL) of AREXVY as an intramuscular injection
Learn how to reconstitute Arexvy appropriately
This Video will guide you through how to reconstitute Arexvy
00:00
00:00
POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000
PM-IE-ABX-WCNT-240001 | Date of Preparation: February 2025
How AREXVY Is Prepared1
Administer 1 dose (0.5 mL) of AREXVY as an intramuscular injection. The need for revaccination has not been established.
AREXVY is supplied in 2 vials that must be combined prior to administration
Vial 1 AS01E Adjuvant suspension component (liquid)
Vial 2: Lyophilized RSVPreF3 antigen component (powder)
Step A:
Cleanse both vial stoppers. Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the adjuvant suspension component (liquid) by slightly tilting the vial. Vial 1 of 2.
Step B:
Slowly transfer entire contents of syringe into the lyophilized RSVPreF3 antigen component vial (powder). Vial 2 of 2.
Step C:
Gently swirl until the powder is completely dissolved.
DO NOT SHAKE VIGORUSLY
Step D:
After reconstitution, withdraw the entire contents of the reconstituted vaccine.
Step E:
Change the needle so that you are using a new needle and administer 0.5 mL intramuscularly.
Step F:
Administer the vaccine intramuscularly.
Use only the supplied adjuvant suspension component (liquid) for reconstitution. The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid. Parenteral drug products should be inspected for particulate matter and not discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccination should not be administered
AREXVY and seasonal influenza vaccine can be administered in the same visit1*
Abbreviations
LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RSVPreF3=recombinant RSV glycoprotein F stabilised in the pre-fusion conformation.
References
- Arexvy SPC, https://www.medicines.ie/medicines/arexvy-powder-and-suspension-for-suspension-for-injection-35441/spc. Accessed February 2025
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
PM-IE-RSA-WCNT-230002 | March 2025
